Bal Pharma Ltd

Bal Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite ongoing challenges in financial performance and long-term growth. The upgrade, effective from 14 Jul 2026, is driven primarily by bullish technical trends and a more attractive valuation profile relative to its pharmaceutical peers.

Bal Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting improved price appeal relative to its historical averages and peer group. This upgrade comes amid a volatile pharmaceutical sector landscape, where the company’s micro-cap status and recent price surge have drawn investor attention despite mixed longer-term returns.

Bal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 July 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price declines and a challenging market environment, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point relative to its peers and historical averages.

Bal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Strong Sell to a Sell rating following a comprehensive review of its financial performance, valuation metrics, and technical indicators. Despite some attractive valuation aspects, the company’s flat quarterly results, weak long-term fundamentals, and deteriorating financial trends have prompted a cautious stance from analysts.

The 50-day moving average has crossed above the 200-day moving average for Bal Pharma Ltd, signalling a golden cross on 8 Jun 2026. Yet, the stock declined 2.41% on the same day, and the monthly technical indicators present a mixed picture. This divergence between the moving averages and price action invites a closer examination of the signal’s reliability.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 1 June 2026. This shift reflects a combination of deteriorating technical indicators, flat financial performance, and a cautious valuation outlook despite some attractive metrics. The company’s shares have also declined sharply, falling 4.61% on the day following the announcement, underscoring investor concerns.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a recent day decline of 6.82%, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point compared to its peers and historical averages.

Bal Pharma Ltd., a Bangalore-based pharmaceutical manufacturer and member of the Micro Laboratories Group, reported a consolidated net profit of ₹3.59 crores for Q4 FY26, representing a dramatic sequential surge of 101.69% from ₹1.78 crores in Q3 FY26. However, the year-on-year comparison reveals a concerning 33.89% decline from ₹5.43 crores in Q4 FY25. The company's shares traded at ₹91.50 on May 29, 2026, down 5.53% from the previous close, reflecting investor caution despite the sequential improvement.

Bal Pharma Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s micro-cap status and flat financial performance continue to weigh on its long-term outlook, but recent technical trends suggest a stabilising price action that has prompted a more favourable, albeit cautious, stance.

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below are based on the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Bal Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.